Möchten Sie immer auf dem neuesten Stand bleiben?

43% of pet owners report that their pets experienced parasite infections, with 75% looking for clearer parasite prevention advice.Veterinarians are seen as the most trusted source of pet health...

This press release is not intended for UK media HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1...

Boehringer and Sitryx Therapeutics partner to advance autoimmune and inflammatory disease research for more personalized, targeted, data driven treatment.

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with...

Boehringer partners with Simcere to develop a bispecific antibody that simultaneously inhibits two drivers of inflammatory bowel disease.

Boehringer launches clinical trial exploring interleukin-11’s potential to go beyond slowing IPF and restore lung function.

Boehringer and Jazz Pharma partner to combine two unique HER2-targeted approaches, aiming to offer new breast cancer treatment options.

  Not intended for UK audiences  Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2Affecting up to 100,000...

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five years.PPF is a rare lung condition, more life-threatening than many...

Harsha Deshmukh has been appointed a member of the Board of Managing Directors with responsibility for IT and Global Business Services effective 1 February 2026  Boehringer Ingelheim announced...